The companies were as diverse as Kleo Pharmaceuticals [previous coverage] , a New Haven based bioscience company developing the research from David Spiegel’s lab at of Yale University. The company is developing what the company says is an entirely new class of immunotherapy drugs by “developing small molecules that emulate biologics.”

Then there is Dream Payments that was the first place winner of CT Innovations Venture Clash, [applications for 2017 are open] the Toronto based fintech company will be establishing itself in Connecticut as part of the funding. Dream Payments provides a cloud-based mobile payment platform for merchants and financial institutions,

CII said in an annoucement “the investments leveraged an additional $58.4 million in capital to further support the growth of these companies.” Of the $12.2 million, CI invested $6.6 million in bioscience and $5.6 million in information technology.

“We were pleased to be able to fuel the growth of more than 30 companies in bioscience and information technology throughout the quarter,” said David Wurzer, executive vice president and chief investment officer at Connecticut Innovations.”